Compare AT&T Inc. (T) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AT&T Inc. vs Zoetis Inc — how do they compare? AT&T Inc. trades at $22.19 (market cap $170.42B), while Zoetis Inc trades at $74.35 (market cap $30.20B). The key difference: AT&T Inc. is far larger — about 5.6× Zoetis Inc's market cap, and AT&T Inc. pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold AT&T Inc. for 118 Days and Zoetis Inc for 70 Days on average.
| T | ZTS | |
|---|---|---|
Market Cap | $170.42B | $30.20B |
Volume | 50,780,036 | 6,175,327 |
Sector | Media | Health |
52-Week High | $29.10 | $147.53 |
52-Week Low | $20.49 | $69.09 |
Typical Hold Time | 118 Days | 70 Days |
Enterprise Value | $315.74B | $37.76B |
Dividend Yield | 4.46% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AT&T (T) trades at $22.105, down 9.68% in the last session, reflecting market concerns despite strong fundamentals. The stock shows solid profitability with 16.94% net margin and attractive valuation at 8.21 P/E. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while technical indicators show mixed signals with RSI at neutral levels.
The outlook remains balanced with analyst consensus at $27.50 target suggesting 24% upside, supported by fiber expansion and wireless growth. Key risks include heavy debt load at $118.44 billion and competitive pressures. The 4% dividend yield provides income support, but investors should monitor execution on debt reduction and revenue trends.
Zoetis (ZTS) trades at $74.38, up 3.96% in the last session, with a bullish technical signal and strong profitability metrics including a 71.67% gross margin and 27.69% net income margin. Recent earnings show mixed results, with a beat in Q2 2026 but a miss in Q1 2026, while Q3 2026 results are pending. The company maintains robust cash flow from operations of $2.90B in 2025 and a solid balance sheet with $1.99B in cash. Analyst consensus is a Buy with a $87.33 price target, though sentiment is tempered by near-term competitive pressures.
The outlook for ZTS is cautiously optimistic, supported by industry-leading margins and a diversified product portfolio, but faces headwinds from U.S. companion animal market weakness and increased competition. Investment opportunity lies in its undervalued P/E of 11.92 relative to growth potential, while risks include pricing erosion and volume declines. The stock's current level near resistance at $74 suggests potential for consolidation before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
